I D
× COMMENTARYCOVER STORYIN THE NEWSNEWSFRONTSCHEMENTATOR + Show More
Chemical EngineeringChementator Briefs
ODH Catalyst Clariant Catalyts (Munich; www.clariant.com) has teamed up with…
BUSINESS NEWSTECHNICAL & PRACTICALFEATURE REPORTFACTS AT YOUR FINGERTIPSTECHNOLOGY PROFILEENGINEERING PRACTICEEQUIPMENT & SERVICESAPPLIED TECHNOLOGIESFOCUSNEW PRODUCTS + Show More

Comment uncategorized

MilliporeSigma opens second manufacturing facility in Carlsbad, Calif.

By Mary Page Bailey |

 MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced the opening of its second Carlsbad, California-based facility, significantly expanding its global CDMO footprint. This new $110 million, 140,000-square foot facility will more than double the company’s existing capacity  to support large-scale commercial and industrial manufacturing for viral gene therapy, in a market expected to grow to $10 billion by 2026.

“Today, most gene therapies target rare diseases, but there is an urgent need to efficiently manufacture these treatments to reach larger patient populations,” said Matthias Heinzel, Member of the Executive Board and CEO, Life Science, Merck KGaA, Darmstadt, Germany. “As a leader in viral vector manufacturing, this increase in capacity and scale is the next step in enabling our customers to bring new curative treatments to market.”

This is the company’s second Carlsbad, California-based facility to serve cell and gene therapy customers driven by the industry’s rapid adoption of viral vector-based therapies. Between the two facilities, there are 30 cleanroom suites to support all aspects of manufacturing from small-to large-scale clinical and commercial production. The new facility leverages cutting-edge suspension technology to enable scalable and cost-effective manufacturing.

“We are continuing to invest in solving cell and gene therapy challenges in development andmanufacturing, working alongside drug developers to industrialize, scale and accelerate the pathto deliver therapies to patients,” Heinzel     added. 

The expansion of the Carlsbad facility adds to the company’s ambition to accelerate growth through investments in the “Big 3”, including the Process Solutions business  unit within the Life Science business sector as a key driver.

The Life Science business of Merck KGaA, Darmstadt, Germany, has proven its commercial execution and global regulatory success as one of the first CDMOs to be granted U.S. Food and Drug Administration and European  Medicines Agency approval for viral vector manufacturing. With nearly 30 years of  experience in cell and gene therapy, the Life Science business of Merck KGaA, Darmstadt, Germany, offers unique CDMO services streamlined as a single, highly experienced provider.

Related Content

Chemical Engineering publishes FREE eletters that bring our original content to our readers in an easily accessible email format about once a week.
Subscribe Now
SICK Solutions for Cleaner Industries - Powerful Transitions
Gain a Digital Line of Sight Across the Whole Lifecycle of the Plant with a Digital Twin
Granulating High Viscous Melts in the Food Industry
How to Select a Pump for Industrial Applications
Temperature Instruments Improve Operations

View More